论文部分内容阅读
BACKGROUND: Huntington disease (HD) is characterized by the progressive death of medium spiny dopamine receptor bearing striatal GABAergic neurons. In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process. METHODS: To evaluate in vivo the involvement of microglia activation in HD, the authors studied patients at different stages of the disease using C(R)- PK11195 PET, a marker of microglia activation, and Craclopride PET, a marker of dopamine D2 receptor binding and hence striatal GABAergic cell function. RESULTS: In HD patients, a significant increase in striatal C(R)- PK11195 binding was observed, which significantly correlated with disease severity as reflected by the striatal reduction in Craclopride binding, the Unified Huntington’ s Disease Rating Scale score, and the patients’ CAG index. Also detected were significant increases in microglia activation in cortical regions including prefrontal cortex and anterior cingulate. CONCLUSIONS: These C(R)- PK11195 PET findings show that the level of microglial activation correlates with Huntington disease (HD) severity. They lend support to the view that microglia contribute to the ongoing neuronal degeneration in HD and indicate that C(R)- PK11195 PET provides a valuable marker when monitoring the efficacy of putative neuroprotecting agents in this relentlessly progressive genetic disorder. u001a
BACKGROUND: Huntington disease (HD) is characterized by the progressive death of medium spiny dopamine receptor bearing striatal GABAgicgic neurons. In addition, microglial activation in the areas of neuronal loss has been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines , and these may contribute to the pathologic process. METHODS: To evaluate in vivo involvement of microglia activation in HD, the authors studying patients at different stages of the disease using C (R) - PK11195 PET, a marker of microglia activation, and Craclopride PET, a marker of dopamine D2 receptor binding and hence striatal GABAergic cell function. RESULTS: In HD patients, a significant increase in striatal C (R) - PK11195 binding was observed, which significantly correlated with disease severity as reflected by the striatal reduction in Craclopride binding, the Unified Huntington’s Disease Rating Scale score, and the patients’ CAG index. Also detected were si gnificant increases in microglia activation in cortical regions including prefrontal cortex and anterior cingulate. CONCLUSIONS: These C (R) - PK11195 PET findings show that the level of microglial activation correlates with Huntington disease (HD) severity. They lend support to the view that microglia contribute to the ongoing neuronal degeneration in HD and indicate that C (R) - PK11195 PET provides a valuable marker when monitoring the efficacy of putative neuroprotecting agents in this relentlessly progressive genetic disorder. u001a